基于DEA-Tobit的创新型医药生物企业创新效率

利用DEA-Tobit两步法对中小板上市的创新型医药生物企业先测算了创新效率，进一步探讨了创新支持政策对创新效率的影响。实证研究表明,大部分企业技术效率不高，纯技术效率有提高，规模效率未达到有效；高强度的政府补贴提高了企业的纯技术效率；税费返还则对纯技术效率有负向影响；创新平台显著提高了技术效率和规模效率。

A DEA-Tobit-based Analysis of the Innovation Efficiency of Pharmaceutical and Biological Innovative Enterprises

As innovative enterprises are important carriers of innovation driven development strategy in China, innovation platforms can effectively stimulate innovation activities. SME Board pharmaceutical and biotech innovative companies are set as samples and the innovative efficiency is assessed with a DEA Tobit two step model. The impact of innovation support policy on innovation efficiency is also discussed. An empirical study shows that most of the enterprises have low technical efficiency. Though the pure technical efficiency has improved, the scale efficiency is still low. What's more, though high strength of government subsidies improves their pure technical efficiency, tax return has negative influence on it. Innovation platforms improve both technical and scale efficiency. Thus, five suggestions are made based on our study.